T cells for advanced synovial sarcoma or myxoid round cell liposarcoma

Transgenic T-cell receptor-based immunotherapies hold the potential to revolutionise the treatment of cancer-testis antigen (CTA)-positive cancers. CTAs are exclusively found in immunologically privileged physiological, non-vitally essential adult testicular germ cells and can be massively overexpressed in cancers.1 One prominently used target for transgenic T-cell receptor-based immunotherapies is intracellular MAGE-A4, which is present in various solid cancers, including synovial sarcoma and myxoid round cell liposarcoma.